KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Debt to Equity (2016 - 2026)

Pacira BioSciences has reported Debt to Equity over the past 15 years, most recently at $0.56 for Q1 2026.

  • For Q1 2026, Debt to Equity rose 47.9% year-over-year to $0.56; the TTM value through Mar 2026 reached $0.56, up 47.9%, while the annual FY2025 figure was $0.54, 28.59% down from the prior year.
  • Debt to Equity for Q1 2026 was $0.56 at Pacira BioSciences, up from $0.54 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.75 in Q4 2024 and troughed at $0.12 in Q2 2024.
  • A 5-year average of $0.37 and a median of $0.4 in 2025 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: plummeted 68.22% in 2023 and later soared 428.36% in 2024.
  • Year by year, Debt to Equity stood at $0.37 in 2022, then plummeted by 61.26% to $0.14 in 2023, then surged by 428.36% to $0.75 in 2024, then fell by 28.59% to $0.54 in 2025, then grew by 4.71% to $0.56 in 2026.
  • Business Quant data shows Debt to Equity for PCRX at $0.56 in Q1 2026, $0.54 in Q4 2025, and $0.52 in Q3 2025.